Ovarian Cancer—An Overview (2020) Bookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)

.

Rectal Cancer—An Overview Bookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Rectal cancer is a subset of colon cancer but worth looking at somewhat differently because of its different location. If you wish to learn more, this presentation from Medscape is clear, detailed, unbiased, and worthy of full attention.

.

Small Cell Lung Cancer (SCLC)—An Overview Bookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Small cell lung cancer is a common, particularly deadly form of lung cancer. If you wish to learn more, this authoritative encyclopedic discussion from Medscape should be very useful (written with a physician audience in mind).

.

Colon Cancer—An Overview Bookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Cancer that develops in the large intestine is known as colon cancer. This comprehensive, credible, and authoritative resourse from Medscape provides in-depth and up-to-date information on this disease.

.

.

FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung Cancer Bookmark

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

NCCN Clinical Practice Guidelines in Oncology: 2020 Updates Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

Go to full news story published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted Therapy Bookmark

Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes: 

A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.

Go to full article published by OncLive.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Maintenance Avelumab Improves Survival in Advanced Bladder Cancer Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial for certain patients with advanced urothelial carcinoma, overall survival was prolonged by about 30% by using supportive care plus maintenance treatment with the drug avelumab, versus supportive care alone.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

In a First, Proton Therapy Bests Radiotherapy in an RCT Bookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial that compared proton beam therapy with standard radiotherapy for esophageal cancer, the two treatments were found to be virtually identical in terms of progression-free survival, overall survival, and quality of life.

Go to full news article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ATIM-14. Results of Phase II Clinical Trial of Oncolytic Herpes Virus G47∆ in Patients with Glioblastoma Bookmark

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.